Trial Profile
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2012
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sorafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2009 Celgene Corporation as company and lead trial centre added as reported by ClinicalTrials.gov.
- 02 Aug 2007 New trial record.